comparemela.com

Latest Breaking News On - Weight management at weill cornell medical center - Page 1 : comparemela.com

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hamburg
Germany
Louisj-aronne
Richard-eisenstadt
Nasdaq
Weight-management-at-weill-cornell-medical-center
Altimmune-inc
Linkedin
Announces-oral-presentation
Pemvidutide-clinical-data
Annual-meeting
European-association

Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced.

United-states
Louisj-aronne
Vipink-garg
Weight-management-at-weill-cornell-medical-center
Altimmune-inc
Linkedin
Nasdaq
Exchange-commission
Weight-management
Weill-cornell-medical-center
Private-securities-litigation-reform-act

Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

28.09.2022 - Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023GAITHERSBURG, Md., Sept. 28, 2022 (GLOBE NEWSWIRE) - Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of . Seite 1

United-states
Louisj-aronne
Altimmune-inc
Weight-management-at-weill-cornell-medical-center
Nasdaq
Weight-management
Weill-cornell-medical-center

vimarsana © 2020. All Rights Reserved.